AR034749A1 - Formulaciones de interferon beta humano - Google Patents

Formulaciones de interferon beta humano

Info

Publication number
AR034749A1
AR034749A1 ARP020102558A ARP020102558A AR034749A1 AR 034749 A1 AR034749 A1 AR 034749A1 AR P020102558 A ARP020102558 A AR P020102558A AR P020102558 A ARP020102558 A AR P020102558A AR 034749 A1 AR034749 A1 AR 034749A1
Authority
AR
Argentina
Prior art keywords
ifn beta
formulations
human beta
beta interferon
dissolved
Prior art date
Application number
ARP020102558A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR034749A1 publication Critical patent/AR034749A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composición farmacéutica estable que contiene interferón beta humano biológicamente activo (IFN beta), preferiblemente IFN beta-1b, producido en un huésped bacteriano, disuelto en una solución basada en agua que contiene un amortiguador de glicina a un pH de entre aproximadamente 2,0 y aproximadamente 4,0. La presente también provee liofilizados estables de IFN beta preparados a partir de IFN beta biológicamente activo disuelto en una solución basada en agua que contiene un amortiguador de glicina a un pH de entre aproximadamente 2,0 y aproximadamente 4,0.
ARP020102558A 2001-07-09 2002-07-08 Formulaciones de interferon beta humano AR034749A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30339501P 2001-07-09 2001-07-09

Publications (1)

Publication Number Publication Date
AR034749A1 true AR034749A1 (es) 2004-03-17

Family

ID=23171889

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102558A AR034749A1 (es) 2001-07-09 2002-07-08 Formulaciones de interferon beta humano

Country Status (7)

Country Link
US (2) US20030118548A1 (es)
JP (1) JP2004538275A (es)
AR (1) AR034749A1 (es)
PE (1) PE20030303A1 (es)
TW (1) TWI241193B (es)
UY (1) UY27373A1 (es)
WO (1) WO2003006053A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
RU2006104023A (ru) * 2003-07-11 2006-07-27 Шеринг Акциенгезельшафт (De) УЛУЧШЕННЫЕ РЕКОМБИНАНТНЫЕ ПОЛИПЕПТИДЫ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА -БЕТА-1b
JPWO2006033453A1 (ja) * 2004-09-22 2008-05-15 学校法人順天堂 インターフェロン作用物質の活性増強剤
PL1809662T3 (pl) * 2004-11-10 2009-07-31 Novartis Vaccines & Diagnostics Inc Dezamidowany interferon-beta
AR053284A1 (es) * 2005-05-19 2007-04-25 Schering Ag Terapia genica de interferon -beta usando un sistema mejorado de expresion regulada
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
PE20070500A1 (es) * 2005-05-19 2007-06-17 Schering Ag Tratamiento de enfermedades usando un sistema mejorado de expresion regulada
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
MX2008001396A (es) * 2005-07-29 2008-04-16 Novartis Ag Metodo y sistema para plegado in vitro de proteinas.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7404589A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het stabiliseren van interferon.
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4289689A (en) * 1980-03-14 1981-09-15 Hoffmann-La Roche Inc. Preparation of homogeneous human fibroblast interferon
DE2943016C2 (de) * 1979-10-24 1984-09-06 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Verfahren zur Reinigung von Interferon
JPS5651995A (en) * 1979-10-05 1981-05-09 Green Cross Corp:The Preparation of interferon
NL7907791A (nl) * 1979-10-23 1981-04-27 Stichting Rega V Z W Werkwijze voor het zuiveren van interferon.
US4315852A (en) * 1980-11-26 1982-02-16 Schering Corporation Extraction of interferon from bacteria
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
IL90047A (en) * 1982-10-19 1992-12-01 Cetus Oncology Corp Cysteine-depleted biologically active muteins other than interferon - '
US4485017A (en) * 1982-12-22 1984-11-27 Cetus Corporation Isolation of human interferon by immunosorbent and high performance liquid chromatography
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
US4643566A (en) * 1984-07-20 1987-02-17 Canon Kabushiki Kaisha Particle analyzing apparatus
DE3628468A1 (de) * 1986-08-21 1988-03-03 Thomae Gmbh Dr K Neue applikationsformen fuer (alpha)-interferone
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2687843A1 (fr) * 1992-02-24 1993-08-27 Motorola Semiconducteurs Transistor bipolaire lateral pnp et procede de fabrication.
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
JP3466765B2 (ja) * 1994-07-27 2003-11-17 キッコーマン株式会社 ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5814485A (en) * 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
HU224222B1 (hu) * 1996-12-24 2005-06-28 Biogen Inc. Stabil folyékony interferon-készítményformák és eljárás interferon stabilizálására
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta

Also Published As

Publication number Publication date
JP2004538275A (ja) 2004-12-24
UY27373A1 (es) 2003-02-28
US20050163752A1 (en) 2005-07-28
PE20030303A1 (es) 2003-06-21
WO2003006053A1 (en) 2003-01-23
US20030118548A1 (en) 2003-06-26
TWI241193B (en) 2005-10-11

Similar Documents

Publication Publication Date Title
ES2569949T3 (es) Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
PL319603A1 (en) Stable aqueous alpha interferon preparations
PT1412384E (pt) Formulação estável de glp-1 modificado
CA2478621A1 (en) Botulinum toxin pharmaceutical compositions
HRP20020880B1 (en) New pharmaceutical composition
EP0693924A4 (en) METHODS OF ADMINISTRATION -i (IN VIVO) OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED IN SUCH METHODS
SE8804629A (es)
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
TR200502189T1 (tr) Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
GEP20053473B (en) High Potency Dihydroergotamine Compositions
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
DE69902875T2 (de) Tts enthaltend ein antioxidans
NZ593190A (en) Factor viii formulations
AR034749A1 (es) Formulaciones de interferon beta humano
MX9710206A (es) Composicion farmaceutica de amiodarone para administracion parenteral.
TW200503754A (en) HSA-free stabilized interferon liquid formulations
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DE60239752D1 (de) Den geschmack verdeckende auslaufsichere formulierung
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
NO20034863D0 (no) Deuterert 3-piperidinopropiofenon og medikamenter inneholdende disse
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
RS20050662A (en) Liquid formulations of tumor necrosis factor-binding proteins
GEP20032970B (en) Pharmaceutical Compositions of Tizoxanide and Nitazoxanide

Legal Events

Date Code Title Description
FB Suspension of granting procedure